Journals / Turkish Journal of Anaesthesiology and Reanimation / 2019 / Cilt: 47 - Sayı: 5

Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats

Pages
392–395
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, in Group2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.Conclusion: We suggest that remifentanil and methylprednisolone used concurrently with sugammadex lead to a decrease in sugammadexreversal effect by giving rise to decrease in its free and active concentrations probably via displacement in rats.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In an in vitro study, lidocaine, remifentanil and methylprednisolone produced inclusion complexes with sugammadex, which lead toa decrease in free and active concentrations of sugammadex.
📊
Key Findings & Data:The aimof the present study was to investigate whether concurrent use of sugammadex with remifentanil, lidocaine and methylprednisolone led to adecrease in the neuromuscular blockade reversal effect of sugammadex produced with neuromuscular blockade agent (NMBA) rocuronium.Methods: The present study included 42 male Wistar rats.
💡
Conclusion & Impact:However, in Group2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.Conclusion: We suggest that remifentanil and methylprednisolone used concurrently with sugammadex lead to a decrease in sugammadexreversal effect by giving rise to decrease in its free and active concentrations probably via displacement in rats.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: In an in vitro study, lidocaine, remifentanil and methylprednisolone produced inclusion complexes with sugammadex, which lead toa decrease in free and active concentrations of sugammadex. When used concurrently with these drugs, it is likely that the time for sugammadexto reverse a neuromuscular blockade is going to be prolonged due to a synergistic pharmacokinetic or pharmacodynamic interaction. The aimof the present study was to investigate whether concurrent use of sugammadex with remifentanil, lidocaine and methylprednisolone led to adecrease in the neuromuscular blockade reversal effect of sugammadex produced with neuromuscular blockade agent (NMBA) rocuronium.Methods: The present study included 42 male Wistar rats. They were randomised into 7 groups, with 6 rats per group. The first group was thecontrol group, the second group received remifentanil and methylprednisolone, the third lidocaine and methylprednisolone, the fourth remifentanil, the fifth lidocaine, the sixth methylprednisolone and the seventh lidocaine and remifentanil. All groups were administered 3.2 mg kg-1 rocuronium for neuromuscular blockade after the administration of study drugs. When the train of four (TOF) value was 0, all groups were administered 16 mg kg-1 sugammadex for the reversal of neuromuscular blockade. With a TOF Watch SX device, the time to TOF ≥0.9 was recorded.Results: When the control group was compared with Groups 3, 4, 5, 6 and 7, no statistically significant difference was found. However, in Group2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.Conclusion: We suggest that remifentanil and methylprednisolone used concurrently with sugammadex lead to a decrease in sugammadexreversal effect by giving rise to decrease in its free and active concentrations probably via displacement in rats.

🔖

Cite This Article

KANDEMİR, T., KANDEMİR, E., AŞKIN, T., MUSLU, S., TUNCEL, G. O., ÜNVER, S. (2019). Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. Turkish Journal of Anaesthesiology and Reanimation, Cilt: 47 - Sayı: 5, 392–395. https://ajindex.com/articles/370473

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24: 29-35. [CrossRef] 2. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, et al. Reversal of rocuronium induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110: 284-94. [CrossRef] 3. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, et al. Effective reversal of moderate rocuroniumor vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106: 283-8. [CrossRef] 4. Zwiers A, den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig 2011; 31: 101-11. [CrossRef] 5. Booij LHDJ, De Boer HD, Van Egmond J. Reversal agents for nondepolarizing neuromuscular blockade: reasons for and development of a new concept. Semin Anesth Periop Med Pain 2002; 21: 92-8. [CrossRef] 6. Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal. Drugs Future 2003; 28: 347-54. [CrossRef] 7. Gulec E, Biricik E, Turktan M, Hatipoglu Z, Unlugenc H. The effect of intravenous dexamethasone on sugammadex reversal time in children undergoing adenotonsillectomy. Anesth Analg 2016; 122: 1147-52. [CrossRef] 8. Ozbilgin S, Yurtlu DA, Küçükoztaş B, Kamacı G, Korkut S, Yurtlu BS, et al. Evaluation of the Effectiveness of Sugammadex for Digoxin Intoxication: An Experimental Study. Cardiovasc Toxicol 2018; 18: 400-6. [CrossRef] 9. Ozer AB, Bolat E, Erhan OL, Kilinc M, Demirel I, Toprak GC. Sugammadex Improves Neuromuscular Function in Patients Receiving Perioperative Steroids. Niger J Clin Pract 2018; 21: 139-42. 10. Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anesthesiol 2006; 72: 97-109. 11. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuro muscular block. Anesth Analg 2010; 111: 120-8.